Navigation Links
Doctors, Biotech Leaders, and Policymakers Gather to Discuss Roadblocks to Innovation and Advancing the 21st Century Cures Initiative
Date:8/25/2014

Boston, MA (PRWEB) August 25, 2014

The Manhattan Institute (MI) and its Project FDA, in partnership with the Tufts Center for the Study of Drug Development, will host the first in a series of public discussions about the reforms necessary to accelerate patient access to life-saving treatments, lower the cost of developing and delivering better treatments, and maintain America’s place as the world leader in bio-innovation. Future events will take place in other leading biotech hubs, including San Francisco and San Diego, CA.

Dr. Andrew von Eschenbach, former FDA commissioner and chairman of MI's Project FDA, will convene key policymakers, patient advocates, academics, and industry experts on August 25 at the Tufts University School of Medicine for a series of panels. Panel topics will include Congress’ 21st Century Cures Initiative, building a better framework for approving new medicines, and using big data to support patient-centered innovation. Panel participants include Rep. Michael Burgess, (TX-26); Dr. Kenneth Kaitin, director and professor, Tufts Center for the Study of Drug Development; Dr. Phillip Sharp, Nobel laureate and professor, MIT; and Jeff Allen, PhD, executive director, Friends of Cancer Research.

Biotech leaders participating include Nick Leschly, president and CEO, Bluebird Bio; Alan Eisenberg, vice president, federal government relations, Celgene; Robert Popovian, senior director, advocacy & professional relations, Pfizer; and Ketan Paranjape, worldwide director of health and life sciences, Intel.

Paul Howard, senior fellow at MI and member of Project FDA, said, “The current drug development paradigm is breaking down – it’s just too expensive and time-consuming. The Manhattan Institute’s Project FDA is focused on helping regulators, companies, patient advocates, and policymakers create a more predictable, transparent, and efficient pathway for bringing safe and effective new therapies to patients.”

“My colleague Peter Huber’s new book, The Cure in the Code, outlines a roadmap for advancing medicine and drug regulation into the 21st Century. What we need to do now is move from vision to reality. Thankfully, Congress’s bipartisan 21st Century Cures Initiative is working to do just that,” Howard added.

The Manhattan Institute is a think tank whose mission is to develop and disseminate new ideas that foster greater economic choice and individual responsibility. Under the leadership of Dr. Andrew von Eschenbach, Project FDA is a Manhattan Institute initiative that aims to help the FDA develop the tools it needs to meet 21st century challenges.

Date: Monday August 25, 2:00 - 4:45 p.m. ET
Panel participants and schedule: http://www.manhattan-institute.org/events/mi-08-25-14.htm
Location: Tufts University School of Medicine, Jaharis Family Center, 150 Harrison Avenue, Room 150, Boston, MA 02111

Read the full story at http://www.prweb.com/releases/2014/08/prweb12115968.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Lancet Neurology: Post-concussion return to play decision for footballers should be made solely by doctors, says new editorial
2. Parents want e-mail consults with doctors, but dont want to pay for them
3. Online USA Doctors, Virtual Doctor Create a New Approach to Help Those with Diabetes
4. Online USA Doctors, Virtual Doctors Present a New, Innovative Way of Treating Anxiety Disorder
5. Leading Edge Telemedicine Company SecondOpinions.com Provides Solution to Obamacare Challenges for Doctors, Patients and Insurance Industry
6. Leading Edge Telemedicine Company SecondOpinions.com Provides Solution to Obamacare Challenges for Doctors, Patients and Insurance Industry
7. Federal Laws Debut this Week to Expose Financial Ties Between Medical Companies and Doctors, Parker Waichman LLP Notes
8. Informatics approach helps doctors, patients make sense of genome data
9. Stanford-StartX Fund-Backed Nirmidas Biotech Raises $2 Million for Diagnostic Research Tools
10. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal
11. KRS Global Biotechnology, Inc. Announces the Compounded Service of Nitroglycerin.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying ... , According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of ... in balancing and detoxifying the body. , A former motivational speaker, Perry A~ has ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show where ... see the most incredible gardens and home improvement experts that attend this amazing show. ... - 700 14th St. Denver CO, is an exciting event that Performance Mobility has ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... , Feb. 8, 2016  Astellas Pharma Inc. President and ... promotion of James Robinson as president, Americas Operations, ... in North and South America , effective ... US, representing the commercial organization in the United ... Masao Yoshida , who is retiring in ...
Breaking Medicine Technology: